Characterising a human endogenous retrovirus(HERV)-derived tumour-associated antigen: enriched RNA-Seq analysis of HERV-K(HML-2) in mantle cell lymphoma cell lines.
Cancer immunotherapy
HERV-K
HERV-K(HML-2)
Leukemia
NGS
RNA-Seq
Transcriptomics
Transposable element
minION
Journal
Mobile DNA
ISSN: 1759-8753
Titre abrégé: Mob DNA
Pays: England
ID NLM: 101519891
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
08
2019
accepted:
14
01
2020
entrez:
15
2
2020
pubmed:
15
2
2020
medline:
15
2
2020
Statut:
epublish
Résumé
The cell-surface attachment protein (Env) of the HERV-K(HML-2) lineage of endogenous retroviruses is a potentially attractive tumour-associated antigen for anti-cancer immunotherapy. The human genome contains around 100 integrated copies (called proviruses or loci) of the HERV-K(HML-2) virus and we argue that it is important for therapy development to know which and how many of these contribute to protein expression, and how this varies across tissues. We measured relative provirus expression in HERV-K(HML-2), using enriched RNA-Seq analysis with both short- and long-read sequencing, in three Mantle Cell Lymphoma cell lines (JVM2, Granta519 and REC1). We also confirmed expression of the Env protein in two of our cell lines using Western blotting, and analysed provirus expression data from all other relevant published studies. Firstly, in both our and other reanalysed studies, approximately 10% of the transcripts mapping to HERV-K(HML-2) came from Env-encoding proviruses. Secondly, in one cell line the majority of the protein expression appears to come from one provirus (12q14.1). Thirdly, we find a strong tissue-specific pattern of provirus expression. A possible dependency of Env expression on a single provirus, combined with the earlier observation that this provirus is not present in all individuals and a general pattern of tissue-specific expression among proviruses, has serious implications for future HERV-K(HML-2)-targeted immunotherapy. Further research into HERV-K(HML-2) as a possible tumour-associated antigen in blood cancers requires a more targeted, proteome-based, screening protocol that will consider these polymorphisms within HERV-K(HML-2). We include a plan (and necessary alignments) for such work.
Sections du résumé
BACKGROUND
BACKGROUND
The cell-surface attachment protein (Env) of the HERV-K(HML-2) lineage of endogenous retroviruses is a potentially attractive tumour-associated antigen for anti-cancer immunotherapy. The human genome contains around 100 integrated copies (called proviruses or loci) of the HERV-K(HML-2) virus and we argue that it is important for therapy development to know which and how many of these contribute to protein expression, and how this varies across tissues. We measured relative provirus expression in HERV-K(HML-2), using enriched RNA-Seq analysis with both short- and long-read sequencing, in three Mantle Cell Lymphoma cell lines (JVM2, Granta519 and REC1). We also confirmed expression of the Env protein in two of our cell lines using Western blotting, and analysed provirus expression data from all other relevant published studies.
RESULTS
RESULTS
Firstly, in both our and other reanalysed studies, approximately 10% of the transcripts mapping to HERV-K(HML-2) came from Env-encoding proviruses. Secondly, in one cell line the majority of the protein expression appears to come from one provirus (12q14.1). Thirdly, we find a strong tissue-specific pattern of provirus expression.
CONCLUSIONS
CONCLUSIONS
A possible dependency of Env expression on a single provirus, combined with the earlier observation that this provirus is not present in all individuals and a general pattern of tissue-specific expression among proviruses, has serious implications for future HERV-K(HML-2)-targeted immunotherapy. Further research into HERV-K(HML-2) as a possible tumour-associated antigen in blood cancers requires a more targeted, proteome-based, screening protocol that will consider these polymorphisms within HERV-K(HML-2). We include a plan (and necessary alignments) for such work.
Identifiants
pubmed: 32055257
doi: 10.1186/s13100-020-0204-1
pii: 204
pmc: PMC7007669
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s). 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Nat Biotechnol. 2011 Nov 13;30(1):99-104
pubmed: 22081020
Viruses. 2015 Mar 04;7(3):939-68
pubmed: 25746218
J Virol. 2017 Dec 14;92(1):
pubmed: 29046454
J Immunol. 2012 Aug 1;189(3):1467-79
pubmed: 22745376
Retrovirology. 2015 Apr 28;12:35
pubmed: 25927962
Clin Cancer Res. 2015 Jul 15;21(14):3241-51
pubmed: 25829402
PLoS Pathog. 2017 Jun 26;13(6):e1006451
pubmed: 28651004
Cancer Discov. 2015 Dec;5(12):1282-95
pubmed: 26516065
J Carcinog. 2013 Mar 16;12:5
pubmed: 23599687
PLoS One. 2013 Oct 18;8(10):e76472
pubmed: 24204631
J Virol. 2005 Oct;79(19):12507-14
pubmed: 16160178
Annu Rev Genet. 2008;42:709-32
pubmed: 18694346
J Reprod Immunol. 2011 Sep;91(1-2):1-8
pubmed: 21840605
BMC Genomics. 2008 Jul 29;9:354
pubmed: 18664271
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Oncoimmunology. 2015 May 26;4(11):e1047582
pubmed: 26451325
Elife. 2016 Mar 26;5:
pubmed: 27016617
Leukemia. 2013 Jul;27(7):1469-78
pubmed: 23307033
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
Cell Host Microbe. 2014 Mar 12;15(3):255-9
pubmed: 24629332
J Virol. 2007 Sep;81(17):9437-42
pubmed: 17581995
J Immunol. 2014 Feb 15;192(4):1343-9
pubmed: 24511094
J Virol. 2001 Oct;75(20):9601-12
pubmed: 11559792
PLoS One. 2013 Aug 30;8(8):e72756
pubmed: 24023643
Front Oncol. 2013 Jul 09;3:180
pubmed: 23847768
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
J Virol. 2014 Jun;88(11):6213-23
pubmed: 24648457
Int J Cancer. 2015 Sep 15;137(6):1249-57
pubmed: 24890612
J Virol. 2003 Oct;77(19):10414-22
pubmed: 12970426
Blood. 2015 Jun 25;125(26):4017-23
pubmed: 25999455
Prostate. 2015 Dec;75(16):1958-71
pubmed: 26384005
Retrovirology. 2014 Jan 28;11:10
pubmed: 24472118
Hum Mutat. 2015 Sep;36(9):903-14
pubmed: 26110913
Oncotarget. 2016 Dec 20;7(51):84093-84117
pubmed: 27557521
J Virol. 2008 Oct;82(19):9329-36
pubmed: 18632860
Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1668-72
pubmed: 14757818
Exp Cell Res. 2009 Mar 10;315(5):849-62
pubmed: 19167380
Mol Biol Evol. 2011 Oct;28(10):2731-9
pubmed: 21546353
Philos Trans R Soc Lond B Biol Sci. 2013 Aug 12;368(1626):20120503
pubmed: 23938752
Nat Rev Microbiol. 2012 May 08;10(6):395-406
pubmed: 22565131
APMIS. 2016 Jan-Feb;124(1-2):67-87
pubmed: 26818263
Mol Biol Evol. 2013 Dec;30(12):2725-9
pubmed: 24132122
J Virol. 2005 Dec;79(24):15573-7
pubmed: 16306628
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
J Clin Invest. 2012 Dec;122(12):4473-89
pubmed: 23143309
Clin Cancer Res. 2015 Jan 15;21(2):471-83
pubmed: 25370465
Dermatology. 2016;232(1):38-43
pubmed: 26580164
Retrovirology. 2011 Nov 08;8:90
pubmed: 22067224
Nature. 2007 Aug 2;448(7153):595-9
pubmed: 17671502
Ann Neurol. 2011 Jan;69(1):141-51
pubmed: 21280084
Cancer Res. 2008 Jul 15;68(14):5869-77
pubmed: 18632641
J Virol. 2012 Jan;86(1):262-76
pubmed: 22031938
Nature. 2001 Feb 15;409(6822):860-921
pubmed: 11237011
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
J Virol. 2014 Sep 1;88(17):9529-37
pubmed: 24920817
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4894-9
pubmed: 15044706
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):E2326-34
pubmed: 27001843
Retrovirology. 2009 Feb 16;6:17
pubmed: 19220907
Curr Biol. 2001 Oct 2;11(19):1531-5
pubmed: 11591322
Bioinformatics. 2018 Sep 15;34(18):3094-3100
pubmed: 29750242
Genome Biol Evol. 2013;5(2):307-28
pubmed: 23338945
Viruses. 2017 May 31;9(6):
pubmed: 28561791
Retrovirology. 2013 Feb 09;10:16
pubmed: 23394165
J Virol. 2009 Dec;83(24):12790-800
pubmed: 19812154
J Virol. 2008 Sep;82(17):8743-61
pubmed: 18562517
Clin Cancer Res. 2013 Nov 15;19(22):6112-25
pubmed: 24081977
Cancer Res. 2002 Oct 1;62(19):5510-6
pubmed: 12359761